[{"id":"918392cb-1535-42f1-925b-b4074b9a3693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04173988","created_at":"2021-01-18T20:21:42.663Z","updated_at":"2024-07-02T16:35:14.617Z","phase":"Phase 1","brief_title":"Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04173988","lead_sponsor":"Children's Hospital of Fudan University","biomarkers":" CD19 • CD4","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • alloCART-19 cell therapy • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/09/2020","start_date":" 01/09/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/20/2025","study_completion_date":" 07/20/2025","last_update_posted":"2024-03-15"}]